Company Announcement
- At Genmab A/S’ Annual General Meeting held today March 17, 2016 the Annual Report for 2015 was approved
- Discharge was given to the Board of Directors and the Executive Management and the year’s profit was carried forward
- Five members of the Board of Directors were re-elected
- PricewaterhouseCoopers was re-elected as auditor of the Company
- The proposal from the Board of Directors on general guidelines for incentive-based remuneration, the proposal on repurchase of own shares, the proposal on the Board of Directors’ remuneration for 2016 and the proposals to amend Article 4A, Article 5A, Article 6, Article 8 and Article 15 in the Articles of Association were adopted
Copenhagen, Denmark; March 17, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) held its Annual General Meeting, today at Tivoli Hotel & Congress Center, Copenhagen, Denmark. At the meeting, Chairman of the Board of Directors Mr. Mats Pettersson gave – on behalf of the Board of Directors – a report on the Company’s activities during the past year. Chief Executive Officer Dr. Jan van de Winkel presented the Company’s plans for 2016, and Chief Financial Officer David Eatwell presented the Annual Report for 2015 endorsed by the auditors. The report was approved and discharge was given to the Board of Directors and the Executive Management.
It was decided that the year’s profit of DKK 838 million be carried forward by transfer to accumulated deficit, as stated in the Annual Report.
Mats Pettersson, Dr. Anders Gersel Pedersen, Pernille Erenbjerg, Dr. Burton G. Malkiel and Dr. Paolo Paoletti were re-elected to the Board of Directors for a one year period.
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company’s auditor.
The General Meeting adopted the proposals from the Board of Directors, as follows:
- The proposal to adopt revised general guidelines for incentive-based remuneration for the Board of Directors and the Executive Management.
- The proposal to authorize the Board of Directors to allow for the Company to repurchase own shares.
- The proposal to adopt the Board of Directors’ remuneration for 2016.
- The proposal to amend Article 4A so that the Board of Directors be authorized to issue shares in the name of the holder instead of bearer shares.
- The proposal to amend Article 5A so that the Board of Directors’ authority to raise convertible loans is increased from a maximum amount of DKK 1.5 billion to a maximum amount of DKK 3 billion and so that the maximum number of new shares that may be issued under the authorization is lowered from 12,500,000 shares to 4,000,000 shares. The authorization is furthermore extended until March 17, 2021.
- The proposal to amend Article 6 so that the Company’s shares are changed from bearer shares to shares issued in the name of the holder.
- The proposal to amend Article 8 so that requirement for the General Meeting to be convened through the IT system of the Danish Business Authority is deleted.
- The proposal to amend Article 15 so that the signatory rule of the Company is clarified.
About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.
Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc.
Company Announcement no. 13
CVR no. 2102 3884
Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark
